<DOC>
	<DOCNO>NCT02547818</DOCNO>
	<brief_summary>This global Phase III , randomize , double-blinded , placebo-controlled study subject evidence early AD . The protocol design determine whether ALZT-OP1 combination treatment ( ALZT-OP1a + ALZT-OP1b ) slow , arrest , reverse cognitive functional decline , subject evidence early stage Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Safety Efficacy Study ALZT-OP1 Subjects With Evidence Early Alzheimer 's Disease</brief_title>
	<detailed_description>This Phase III study design randomize , double-blinded , placebo-controlled study subject evidence early AD . The study evaluate safety tolerability , efficacy measure CDR-SB , determine combination therapy ALZT-OP1 slow , arrest , reverse cognitive functional decline early stage AD population . Subjects randomly assign one four treatment arm : Group I consist ALZT-OP1a ( cromolyn ) inhalation , plus oral placebo tablet ; OR Group II arm , consist ALZT-OP1 combination therapy ALZT-OP1a ( cromolyn ) inhalation , plus ALZT-OP1b ( ibuprofen ) tablet oral administration ; OR Group III arm , consist inhale placebo , plus ALZT-OP1b ( ibuprofen ) tablet oral administration ; OR Group IV placebo arm , consist inhale placebo plus oral placebo tablet . A minimum 400 evaluable subject randomize receive one four possible treatment assignment contain various combination active study drug placebo . To account subject dropout ( estimate rate 30 % ) , anticipate 600 ( 150 subject per treatment arm ) may recruit randomized , achieve minimum 100 evaluable subject per treatment arm .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>5579 year old ; ≥ 8 year education ; Study partner available frequent contact participant ( e.g . average 10 hour per week ) , accompany participant clinic visit duration protocol ; Evidence early AD , define follow : 1 . Memory complaint subject study partner verify study partner ; 2 . Objective memory impairment age , document score education adjust cutoff Logical Memory II subscale ( Delayed Paragraph Recall ) Wechsler Memory Scale Third Edition ( maximum score 25 ) : ≤ 8 16 year education , ≤ 4 815 year education ; Essentially preserve general cognitive function ; Largely intact functional activity ; Not demented ; Cerebrospinal fluid ( CSF ) biomarker result consistent early AD , include CSF Aβ42 level ≥ 180 pg/mL ≤ 690 pg/mL ; Clinical Dementia Rating ( Global ) = 0.5 ; Memory Box score must least 0.5 ; Must fluent language cognitive test material administer ; Stability permit medication 4 week prior study start ; subject receive acetylcholinesterase inhibitor and/or memantine stable dose medication least 12 week prior study start every effort maintain stable dose duration study ; Visual auditory acuity adequate neuropsychological testing ; Good general health disease expect interfere study ; Must provide write informed consent APOe4 genotype testing ; Must provide write informed consent CSF sampling . Any significant neurological disease suspect incipient AD , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic default know structural brain abnormality ; Major depressive episode , describe Diagnostic Statistical Manual Mental Disorders ( DSMIV ) within past 6 month , could lead difficulty comply protocol ; History schizophrenia bipolar disorder ( DSMIV criterion ) ; History alcohol substance abuse dependence within past 3 year ( DSMIV criterion ) ; Currently take medication could lead difficulty comply protocol ; subject must stable dose current medication 4 week prior study entry , exception acetylcholinesterase inhibitor and/or memantine , must stable dose least 12 week prior study entry ; Investigational agent prohibit one month prior entry duration trial ; Currently take medication know CYP2C9 inducer ( i.e . carbamazepine rifampicin ) ; Currently take cromolyn , take cromolyn , within past 12 month ; Chronic daily use highdose NSAID osteoarthritis , rheumatoid arthritis , chronic inflammatory disease ( `` chronic '' define 3200 mg/day &gt; 2 week ) ; Chronic daily use aspirin exceed standard care guideline low dose aspirin therapy prevention stroke and/or recommended us ; Allergy cromolyn ( also know Intal® , Nasalcrom® , Opticrom® , Gastrocrom® , etc . ) ; Allergies ibuprofen ( Advil® , Motrin® , Nuprin® , etc . ) aspirin ; Clinically significant respiratory disorder impair respiratory effort difficulty take inhaled drug ; Uncontrolled chronic asthma ; Abnormal pulmonary function test , define protocol : FEV1/FVC &lt; predict value subject AND FEV1 &lt; 70 % predict value , indicate moderate severe respiratory obstruction ; Taking inhale protein product chronic basis ; Any significant systemic illness unstable medical condition could lead difficulty comply protocol ; Pregnancy lactation female subject childbearing potential ( i.e. , &lt; two year postmenopausal surgically sterile ) ; For sexually active male subject , unwillingness incapability use appropriate contraception method ; Severe renal hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Early stage AD</keyword>
	<keyword>MCI</keyword>
	<keyword>aMCI</keyword>
	<keyword>prodromal</keyword>
	<keyword>Memory loss</keyword>
	<keyword>Memory problem</keyword>
	<keyword>Aging</keyword>
	<keyword>Early Alzheimer 's Disease</keyword>
	<keyword>Early AD</keyword>
</DOC>